Increased C-reactive protein levels are linked to an increased risk of heart attacks; however, the C-reactive protein test does not identify the direct cause of inflammation but rather the level of inflammation produced by other factors. The C-reactive protein test is utilized in patients who have a low chance of having a heart attack in the next few years, about 5% to 10%.
Frequently Asked Questions
The market is segmented based on Global C-Reactive Protein Testing Market Segmentation, By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others), Detection Range (hs-CRP, Conventional CRP, cCRP), Disease (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Syphilis, Inflammatory Diseases, Diabetes, Others), Analysis Mode (Serum, Plasma, Blood), End-User (Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, Others), Product Type (Kits, Reagents) - Industry Trends and Forecast to 2032
.
The Global C Reactive Protein Testing Market size was valued at USD 5.72 USD Billion in 2024.
The Global C Reactive Protein Testing Market is projected to grow at a CAGR of 1.15% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
